Harmony Biosciences (NASDAQ:HRMY) Given “Buy” Rating at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Harmony Biosciences (NASDAQ:HRMY) in a research report released on Thursday, Benzinga reports. They currently have a $52.00 price target on the stock.

HRMY has been the subject of several other research reports. Citigroup started coverage on Harmony Biosciences in a research note on Friday, June 21st. They set a buy rating and a $48.00 price target for the company. UBS Group started coverage on Harmony Biosciences in a research note on Tuesday. They set a buy rating and a $56.00 price target for the company. Two research analysts have rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Harmony Biosciences presently has a consensus rating of Moderate Buy and a consensus target price of $41.33.

Harmony Biosciences Price Performance

Shares of NASDAQ HRMY opened at $37.76 on Thursday. The company has a current ratio of 3.13, a quick ratio of 3.09 and a debt-to-equity ratio of 0.32. Harmony Biosciences has a twelve month low of $18.61 and a twelve month high of $39.26. The stock has a 50 day moving average of $34.41 and a two-hundred day moving average of $31.94. The stock has a market cap of $2.14 billion, a P/E ratio of 16.35, a P/E/G ratio of 0.71 and a beta of 0.73.

Harmony Biosciences (NASDAQ:HRMY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.24. Harmony Biosciences had a return on equity of 22.97% and a net margin of 17.53%. The company had revenue of $172.80 million during the quarter, compared to analysts’ expectations of $172.53 million. During the same quarter in the previous year, the business earned $0.56 earnings per share. The firm’s revenue for the quarter was up 28.8% on a year-over-year basis. On average, research analysts forecast that Harmony Biosciences will post 2.19 earnings per share for the current year.

Institutional Trading of Harmony Biosciences

Several large investors have recently bought and sold shares of HRMY. TFO Wealth Partners LLC grew its holdings in Harmony Biosciences by 98,700.0% in the fourth quarter. TFO Wealth Partners LLC now owns 988 shares of the company’s stock valued at $32,000 after purchasing an additional 987 shares during the last quarter. Quadrant Capital Group LLC boosted its stake in shares of Harmony Biosciences by 47.5% during the fourth quarter. Quadrant Capital Group LLC now owns 1,022 shares of the company’s stock valued at $33,000 after acquiring an additional 329 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Harmony Biosciences during the second quarter valued at $36,000. Quarry LP acquired a new stake in shares of Harmony Biosciences during the second quarter valued at $62,000. Finally, Headlands Technologies LLC boosted its stake in shares of Harmony Biosciences by 1,608.1% during the second quarter. Headlands Technologies LLC now owns 2,545 shares of the company’s stock valued at $77,000 after acquiring an additional 2,396 shares during the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.